Tesamorelin is the visceral fat specialist. It's a GHRH (growth hormone-releasing hormone) analog, FDA-approved as Egrifta for reducing the deep abdominal fat that wraps around your organs. This isn't the fat you can pinch. It's the fat your doctor sees on a DEXA scan and worries about. Tesamorelin triggers your pituitary to release growth hormone in a burst-and-fade pattern, and that GH signal specifically mobilizes visceral fat. Clinical trials showed 10-15% visceral fat reduction over 26 weeks. A separate study showed 37% hepatic (liver) fat reduction. The scale won't move much. Don't expect it to. But the imaging shows the dangerous organ-wrapping fat actually shrinking. That's what separates tesamorelin from GLP-1s like semaglutide: GLP-1s shrink everything (including muscle). Tesamorelin targets visceral fat while preserving lean mass.
Tesamorelin Protocol
Dose: 1-2mg per day | Frequency: Once daily, evening preferred | Cycle: 26 weeks is the studied duration, some run longer with medical supervision | Route: SubQ
Inject in the abdomen. The FDA-approved dose is 2mg daily (Egrifta SV). Compounded versions often start at 1mg. Evening timing aligns with your natural natural growth hormone surge during early sleep. Results take 8-12 weeks to become visible. This is a slow burn, not a quick fix.
Tesamorelin Effects
Visceral fat reduction (75%). 10-15% reduction in visceral fat over 26 weeks in clinical trials
Elevated IGF-1 (70%). Your IGF-1 goes up and stays up from the daily growth hormone boost. Recovery, sleep, and body composition all benefit.
Improved body composition (60%). Waist circumference decreases even when scale weight stays the same
Better lipid profile (45%). Cholesterol and triglycerides trend in the right direction. Your bloodwork gets happier.
Tesamorelin Side Effects
Injection-site bruising (35%). You'll bruise where you pin more than with most compounds. Rotate sites and it's manageable.
Injection-site redness (25%). Red and irritated around the injection spot. Usually gone by the next day.
Joint pain (15%). Achy joints from the elevated GH. It's a known class effect. If it's bothering you, your GH is running high.
Water retention / puffiness (10%). Puffy hands and feet from mild water retention. Usually settles after the first couple weeks.
Muscle aches (8%). Mild muscle soreness. Not workout-related. Just a GH thing. Manageable.
Tesamorelin Dosing by Use Case
Condition
Dose
Duration
Notes
Visceral fat reduction
2mg SubQ daily, abdomen
26 weeks (FDA-studied duration)
The primary indication. Tesamorelin selectively reduces visceral fat without significantly affecting subcutaneous fat. 10-15% visceral fat reduction in Phase 3 trials. This is the fat wrapping your organs, not the fat you can pinch. DEXA or CT scan before and after is the real measure, not the scale.
Liver fat reduction (NAFLD/MASLD)
2mg SubQ daily
12-26 weeks
Stanley et al. showed 37% hepatic fat reduction in HIV patients with fatty liver. The mechanism works regardless of HIV status: growth hormone pulls the stored fat out of your liver and burns it. If you have elevated liver enzymes or fatty liver on imaging, this is the specific angle. Track ALT/AST before and after.
GH optimization with visceral fat focus
1-2mg SubQ daily, evening
8-12 weeks on, 4 weeks off, or continuous with monitoring
For people who want GH benefits (recovery, sleep, body comp) but have visceral fat as their primary concern. Tesamorelin is a GHRH analog. It works through the same pathway as CJC-1295 but has FDA human trial data behind it. It's the more evidence-backed option if visceral fat is the target.
Stacked with GLP-1 for full-spectrum fat reduction
1-2mg SubQ daily (tesamorelin) + GLP-1 at prescribed dose
12-26 weeks
GLP-1s (semaglutide, tirzepatide) reduce total body weight including muscle. Tesamorelin targets visceral fat and preserves lean mass. The stack gives you appetite suppression from the GLP-1 + selective visceral fat mobilization from tesamorelin. Different mechanisms, complementary effects. Some protocols add this specifically to protect body composition during aggressive GLP-1 weight loss.
Tesamorelin Results Timeline
Week 1-4, GH axis activating: IGF-1 levels start rising. You won't see visible changes yet. Some water retention and joint aches as GH elevation takes effect. Sleep may deepen if dosing in the evening. This phase is about what's happening inside, not what you see in the mirror.
Week 4-8, Internal changes begin: Visceral fat mobilization is underway but not visible externally. Waist measurements may start moving even though scale weight hasn't. Some people notice clothes fitting differently around the midsection. Liver enzymes may start trending down if elevated at baseline.
Week 8-16, Visible body composition shift: This is when people see and feel the difference. Midsection tightens. Face may look leaner. The changes are subtle compared to GLP-1 weight loss because tesamorelin is specifically targeting visceral fat, not total mass. DEXA scan or waist circumference tracking shows the real story.
Week 16-26, Peak visceral fat reduction: The clinical trial endpoint. 10-15% visceral fat reduction. Liver fat continues improving. Lipid panels improving. The question at this point is whether to continue, cycle off, or transition to maintenance dosing. No published data on what happens beyond 26 weeks in non-HIV populations.
Frequently Asked Questions About Tesamorelin
What is tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It's FDA-approved as Egrifta for reducing visceral abdominal fat in HIV patients with lipodystrophy. It works by stimulating your pituitary gland to release growth hormone in a natural, burst-and-fade pattern. That GH signal specifically mobilizes visceral (organ-wrapping) fat for oxidation. It completed two Phase 3 human clinical trials and has a branded prescription product, making it one of the most evidence-backed compounds in this space.
What is the best tesamorelin dosage?
The FDA-approved dose is 2mg subcutaneously once daily (Egrifta SV formulation). Compounded versions often start at 1mg daily and increase to 2mg after 2-4 weeks. Inject in the abdomen. Evening dosing is preferred because it aligns with your natural nighttime GH surge. The clinical trials ran for 26 weeks. Results become visible at 8-12 weeks. Don't expect rapid changes. This targets deep visceral fat, not the fat you can pinch.
What are the side effects of tesamorelin?
Injection-site bruising (35%), redness (25%), joint pain (15%), peripheral edema/water retention (10%), and muscle aches (8%). The joint pain and water retention are class effects of elevated GH. They usually settle after 2-3 weeks. If joint pain persists, your GH is running too high. In clinical trials, tesamorelin was not associated with increased diabetes risk despite GH's theoretical effect on blood glucose. Monitor fasting glucose and IGF-1 periodically.
Tesamorelin vs ipamorelin: what's the difference?
Both stimulate growth hormone release but through different receptors. Tesamorelin is a GHRH analog (hits the GHRH receptor on the pituitary). Ipamorelin is a ghrelin-pathway compound (hits a different receptor on the pituitary). Tesamorelin has FDA approval, human Phase 3 data, and proven visceral fat reduction. Ipamorelin has no FDA approval and relies on community protocols. Tesamorelin is more expensive and requires daily dosing. Some protocols stack both, using tesamorelin for the evidence-backed visceral fat effect and adding ipamorelin for the complementary ghrelin-pathway pulse.
Does tesamorelin reduce liver fat?
Yes. A study by Stanley et al. showed 37% hepatic fat reduction in HIV patients treated with tesamorelin. Fourman et al. showed that visceral fat reduction with tesamorelin was associated with improved liver enzymes. The mechanism: growth hormone mobilizes triglycerides stored in liver tissue for oxidation. This effect works through the same pathway regardless of HIV status. If you have fatty liver (NAFLD/MASLD) with elevated ALT/AST, this is the specific angle to discuss with a clinician.
How does tesamorelin compare to GLP-1s like semaglutide?
Different tools for different problems. Semaglutide suppresses appetite and produces total body weight loss (15-22% in trials), including muscle and subcutaneous fat. Tesamorelin doesn't suppress appetite. It specifically reduces visceral fat while preserving lean mass. The scale moves dramatically on semaglutide. It barely moves on tesamorelin. But tesamorelin targets the metabolically dangerous fat that GLP-1s don't specifically address. Some protocols stack both: GLP-1 for appetite and total weight, tesamorelin to protect body composition and target visceral stores.
How do you reconstitute tesamorelin?
For compounded lyophilized vials: add 2mL of bacteriostatic water. Swirl gently. Never shake. The concentration depends on your vial size. For a 2mg vial with 2mL water, the entire vial is one dose. For larger vials, calculate your dose in units using our calculator. Inject subcutaneously in the abdomen. Use a 30 gauge, 0.5 inch needle. Refrigerate after reconstitution. Use within 28 days.
Why is tesamorelin FDA-approved but ipamorelin isn't?
Tesamorelin was developed by Theratechnologies and put through the full FDA approval process: Phase 1, 2, and 3 clinical trials in humans, for a specific medical indication (HIV-associated lipodystrophy). That costs hundreds of millions of dollars and takes years. Ipamorelin was researched primarily in animal studies and small human studies. No company invested in the full FDA trial program for it. FDA approval doesn't mean one is better than the other. It means one had a corporate sponsor willing to fund the regulatory process.
Strong evidence. FDA-approved as Egrifta for reducing visceral fat in HIV patients with lipodystrophy. Two Phase 3 trials showed significant visceral fat reduction without affecting subcutaneous fat. Also showed 37% hepatic fat reduction in a separate NAFLD study. One of the few compounds with actual FDA approval and multiple human RCTs.
Approval status: FDA-approved (branded)
References
Falutz J, Allas S, Blot K, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr, 2010. PMID 20101189
Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials. J Clin Endocrinol Metab, 2010. PMID 20554713
Stanley TL, Feldpausch MN, Oh J, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis, 2012. PMID 22495074
Fourman LT, Czerwonka N, Engstrom RL, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS, 2017. PMID 28832410
Mangili A, Falutz J, Engstrom RL, et al. Predictors of Treatment Response to Tesamorelin in HIV-Infected Patients with Excess Abdominal Fat. PLoS One, 2015. PMID 26457580
Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother, 2012. PMID 22298602
Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020. PMID 32573488
Storage
Lyophilized: Refrigerate at 2-8C. Protect from light.
Reconstituted: Refrigerate. Use within 28 days for compounded, or per manufacturer instructions for branded.
Water: Bacteriostatic water, 2mL per vial for compounded versions.
Needle: 30 gauge, 0.5 inch for subcutaneous injection in the abdomen
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
